Navigation Links
SenesTech, Inc. Commences Product Registration Process With Australian Government
Date:11/10/2008

g and Regulations for SenesTech, Inc. "Just as FDA approval is critical for pharmaceuticals in the U.S., moving ContraPest(R) through the regulatory process with the APVMA will secure our ability to manufacture the product under Australian governmental oversight using Good Manufacturing Practices. This guarantees a high standard of product quality and consistency, regardless of a particular manufacturer's location."

For additional information contact Everett Hale at ehale@senestech.com or visit http://www.senestech.com. ContraPest(R) is projected to be available for commercial use in the spring of 2010.

ABOUT: (SenesTech, Inc.) SenesTech is a platform technology company located in Flagstaff, Arizona on the Northern Arizona Center for Emerging Technology campus. SenesTech specializes in environmentally neutral fertility control products for companion animals and wildlife population control.


'/>"/>
SOURCE SenesTech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
2. Arizona-Based SenesTech, Inc., Partners With Australia to Stop Starvation Due to Rice Shortages
3. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
4. Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share
5. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
6. Phase 1b/2a Program Commences for RVX-208
7. GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period
8. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
9. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
10. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
11. Arbios Commences Process to Seek European Marketing Approval for SEPET(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... announced data presentations on its novel oral JAK2 inhibitor, ... Meeting and Exposition in New Orleans. ,, Data will ... 1 dose-escalation trial of SB1518 detailing its safety, tolerability ... 100 to 600 mg. These doses were administered once ...
(Date:12/2/2009)... /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,("Simcere" or the "Company") ... company,specializing in the development, manufacturing, and marketing of ... that 105 of,its drugs have been included in ... by China,s Ministry of Human Resources and Social,Security ...
(Date:12/2/2009)... -- The world is going through,extraordinary times; markets are ... industries. It turns out that the pharma industry has ... take a,vacation. , During the ... Johnson & Johnson inaugurated an R&D center in Shanghai, ...
(Date:12/2/2009)... Dec. 2 According to the National Institute of Health, ... already have some stage of diabetic retinopathy. Diabetic retinopathy, ... a major cause of blindness in people with diabetes and ... fact, up to 80 percent of all patients who,ve had ...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4
... synthesis inhibitor provides additional treatment option for asthma patients ... ... medications, NAPA, Calif., Sept. 27 Dey, L.P., an,affiliate ... ZYFLO CR(TM) (zileuton) extended-release tablets with its,marketing partner, Critical Therapeutics, Inc. ...
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ), ... commercializing proprietary product candidates for the treatment,of ... data from,preclinical studies of ANX-514 (docetaxel emulsion) ... Cancer Research (AACR), National Cancer,Institute (NCI) and ...
... The National,Alliance for Thrombosis and Thrombophilia (NATT) today announced ... that will serve as,building blocks for its efforts to ... one million Americans who develop a blood clot. ... and Prevention (CDC),grants to "launch a national wake-up call ...
Other Biology Technology:Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma 2Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma 3ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 2ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 3ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 4CDC Awards NATT Funding to Improve Blood Clot Awareness 2CDC Awards NATT Funding to Improve Blood Clot Awareness 3
(Date:12/3/2009)... WALL, N.J., Dec. 3 BIO-key International, Inc. ... public safety and finger-based biometric identification solutions, announced ... Special Shareholder Meeting held today approved the sale ... Mobile Systems Inc. Of the shares voted, 98.6% ...
(Date:12/3/2009)... panels that repels grime and dirt? Expanded battery storage ... University research, just published in Nature Nanotechnology , ... level that could make these futuristic visions come true ... range of 100 nanometers (roughly one-billionth of a meter) ...
(Date:12/3/2009)... 3, 2009) Van Andel Research Institute (VARI) ... (ABA) works at the molecular level to help plants respond ... findings, published in the journal Nature , could help ... and combat global food shortages. The findings could also ...
Breaking Biology News(10 mins):BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3A window that washes itself? 2VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Regence Employees Give Nearly 241 3 Million to Charity in Two Week Period 61674 1Regence Employees Give Nearly 241 3 Million to Charity in Two Week Period 61674 2GettingHired Announces Additional Funding for Continued Growth as Well as R 26amp 3BD of New Product for Long Term Disability and Workers Comp 61669 1GettingHired Announces Additional Funding for Continued Growth as Well as R 26amp 3BD of New Product for Long Term Disability and Workers Comp 61669 2GettingHired Announces Additional Funding for Continued Growth as Well as R 26amp 3BD of New Product for Long Term Disability and Workers Comp 61669 3IPC The Hospitalist Company Acquires Two New England Practices 61664 1IPC The Hospitalist Company Acquires Two New England Practices 61664 2
... of transgenic crops are the focus of numerous ... journal PloS ONE, which was carried out by ... of Ted Turlings, professor in chemical ecology at ... most transgenic maize lines were significantly more susceptible ...
... 29, 2007 Capuchin monkeys are playful, inquisitive primates ... cognitive abilities. New research now shows that just ... the organization of the brain, specifically in the corpus ... , A recently published paper by Associate ...
... are continuously happening in hospitals. One of these stories ... the World Journal of Gastroenterology because of its shining ... comfort to many families. , It is about a ... Nagasaki University Hospital, Japan in 2004. This patient was ...
Other Biology News:Transgenic maize is more susceptible to aphids 2Influence of sex and handedness on brain is similar in capuchin monkeys and humans 2Clearance of hepatitis C viral infection after liver transplantation 2
Co-precipitant is free of background polynucleotides,Dnases,Rnases, proteases. 20mg/ml...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
RAB32, member RAS oncogene family, mRNA (cDNA clone MGC:13500 IMAGE:4280407), complete cds...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
Biology Products: